Get the Stockscreener App
23.06
3.41%
0.76
After Hours:
23.37
0.31
+1.34%
Greenwich Lifesciences Inc stock is traded at $23.06, with a volume of 89,717.
It is up +3.41% in the last 24 hours and up +4.68% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
See More
Previous Close:
$22.30
Open:
$23
24h Volume:
89,717
Relative Volume:
0.55
Market Cap:
$319.49M
Revenue:
-
Net Income/Loss:
$-19.48M
P/E Ratio:
-15.75
EPS:
-1.4641
Net Cash Flow:
$-8.59M
1W Performance:
+6.76%
1M Performance:
+4.68%
6M Performance:
+180.54%
1Y Performance:
+145.84%
1-Day Range:
$22.80
$23.74
1-Week Range:
$21.41
$24.90
52-Week Range:
$7.78
$34.10
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
23.06 | 308.96M | 0 | -19.48M | -8.59M | -1.4641 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
(GLSI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Greenwich LifeSciences delays annual report filing - Investing.com UK
Greenwich LifeSciences delays annual report filing By Investing.com - Investing.com South Africa
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing - The Manila Times
Europe trial enrollment jump leaves Greenwich finalizing 10-K figures - Stock Titan
GLSI Stock Price, Quote & Chart | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
Why did Greenwich LifeSciences stock soar pre-market today? - MSN
Why is GLSI stock rising today? - MSN
Greenwich LifeSciences receives Nasdaq notice regarding late Form 10-K filing - MSN
Greenwich LifeSciences (NASDAQ:GLSI) Cut to "Sell" at Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Greenwich LifeSciences (GLSI) and Actinogen Medical (OtherATGGF) - The Globe and Mail
GLSI Technical Analysis | Trend, Signals & Chart Patterns | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
HC Wainwright Has Bearish Estimate for GLSI FY2026 Earnings - MarketBeat
ASCO 2026 to feature Greenwich LifeSciences research poster - Traders Union
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026 - ChartMill
GLSI (Greenwich LifeSciences Inc.) reports narrow Q3 2025 EPS beat, shares climb 2.36 percent on positive investor sentiment.Hedge Fund Inspired Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Breast cancer immunotherapy study lands ASCO 2026 poster slot - Stock Titan
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - ChartMill
H.C. Wainwright Maintains Greenwich LifeSciences(GLSI.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Nasdaq flags Greenwich LifeSciences over delayed 2025 annual report - Stock Titan
(GLSI) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Why Did GLSI Stock Rise Pre-Market Today? - Stocktwits
Greenwich LifeSciences shares rise on breast cancer vaccine trial data By Investing.com - Investing.com Canada
Greenwich LifeSciences unveils preliminary FLAMINGO-01 open label data at AACR Meeting - Traders Union
Breast cancer immunotherapy shows 4x immune response in Phase III data - Stock Titan
Is Greenwich LifeSciences (GLSI) stock still attractive (Bullish Sentiment) 2026-04-18Stock Idea Sharing Hub - Xã Thanh Hà
Greenwich LifeSciences (GLSI) Stock Rule Based Trade (Investors Pile In) 2026-04-16Shared Buy Zones - Xã Châu Thành
Greenwich LifeSciences (GLSI) Stock Rights Issue (At Lows) 2026-04-15Scalping - UBND thành phố Hải Phòng
Greenwich Lifesciences Provides Clinical Trial and Pipeline Update - National Today
Greenwich LifeSciences reports Q1 cash balance of $10.5 million By Investing.com - Investing.com Australia
Strategic financing update revealed by Greenwich LifeSciences - Traders Union
Greenwich LifeSciences, Inc. Provides Financial Updates and Progress on FLAMINGO-01 Phase III Trial for Breast Cancer Immunotherapy GLSI-100 - Quiver Quantitative
Greenwich LifeSciences reports Q1 cash balance of $10.5 million - Investing.com
Greenwich LifeSciences Provides Update on Financing Strategy - ChartMill
Greenwich LifeSciences (GLSI) Expected to Announce Earnings on Tuesday - MarketBeat
Portfolio Shifts: Can Greenwich LifeSciences Inc expand into new markets2026 Recap & Detailed Earnings Play Strategies - baoquankhu1.vn
Greenwich Lifesciences Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Aug Retail: Will Greenwich LifeSciences Inc benefit from current market trendsTrade Risk Assessment & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Will Greenwich LifeSciences Inc benefit from current market trends2026 Market Outlook & Weekly Hot Stock Watchlists - baoquankhu1.vn
(GLSI) Risk Channels and Responsive Allocation - Stock Traders Daily
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 - ADVFN
Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential - Sahm
Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim - Seeking Alpha
Greenwich LifeSciences files patent claims for breast cancer therapy By Investing.com - Investing.com South Africa
Greenwich LifeSciences advances new patent claims after FLAMINGO-01 data show statistically significant immune response - Traders Union
Greenwich LifeSciences files patent claims for breast cancer therapy - Investing.com
Greenwich Lifesciences Provides Update On Patent Claims Potentially Doubling Gp2 Market Potential - TradingView
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Greenwich Lifesciences Inc Stock (GLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Jan 12 '26 |
Buy |
27.54 |
2,900 |
79,866 |
5,602,302 |
| Patel Snehal | CEO and CFO |
Dec 31 '25 |
Buy |
21.36 |
4,300 |
91,848 |
5,599,402 |
| Patel Snehal | CEO and CFO |
Dec 30 '25 |
Buy |
21.73 |
2,900 |
63,017 |
5,595,102 |
| Patel Snehal | CEO and CFO |
Dec 18 '25 |
Buy |
12.62 |
4,100 |
51,742 |
5,592,202 |
| Patel Snehal | CEO and CFO |
Nov 25 '25 |
Buy |
8.37 |
4,600 |
38,502 |
5,588,102 |
| Patel Snehal | CEO and CFO |
Nov 07 '25 |
Buy |
8.43 |
10,600 |
89,358 |
5,583,502 |
| Patel Snehal | CEO and CFO |
Oct 31 '25 |
Buy |
9.26 |
2,300 |
21,298 |
5,572,902 |
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):